Standalone Financial Results (Q1 FY27)

  • Revenue from operations: ₹4,464.71 million
  • Other income: ₹37.87 million
  • Total Income: ₹4,502.58 million
  • Profit before exceptional items and tax: ₹512.25 million
  • Exceptional items (gain)/loss (net): ₹16.70 million gain (reversal of excess provision for gratuity and compensated absences under new Labour Codes)
  • Profit before tax: ₹512.25 million
  • Total tax expense: ₹0.00 million
  • Profit after tax: ₹512.25 million
  • Other Comprehensive Income: ₹0.06 million
  • Total Comprehensive Income: ₹512.31 million
  • Paid-up equity share capital: ₹114.64 million
  • Earnings per share (EPS) - Basic & Diluted: Not annualized and not disclosed in the standalone statement.

Consolidated Financial Results (Q1 FY27)

  • Revenue from operations: ₹4,490.23 million
  • Other income: ₹38.02 million
  • Total Income: ₹4,528.25 million
  • Profit/(loss) before exceptional items and tax: ₹245.94 million
  • Exceptional items (gain)/loss (net): ₹(43.00) million loss (legal charges related to legacy litigation of a subsidiary)
  • Profit/(Loss) before tax: ₹202.94 million
  • Total tax expense (credit): ₹(47.03) million
  • Profit/(Loss) after tax: ₹249.97 million
  • Other Comprehensive Income: ₹35.95 million
  • Total Comprehensive Income: ₹285.92 million
  • Paid-up equity share capital: ₹114.64 million
  • Earnings per share (EPS) - Basic & Diluted: ₹2.18

Exceptional Items Detail

Standalone (Q1 FY27): A net gain of ₹16.70 million due to the reversal of an excess provision for gratuity and compensated absences that was initially recognized in Q3 FY26.

Consolidated (Q1 FY27): A net loss of ₹43.00 million attributed to legal charges from the "Prestige litigation regarding the Sputnik vaccine."

Segment Information

The Company's and the Group's operations relate to only one reportable segment: Contract Development and Manufacturing Organization (CDMO) for the development and manufacture of pharmaceutical products and associated services.

Significant Litigation Contingency (Note 6)

Biolexis Pte Limited, a step-down subsidiary, is involved in an arbitration proceeding with Prestige Biopharma Limited ('Prestige') at the Singapore International Arbitration Centre (SIAC).

Prestige has claimed USD 136.32 million (approx. ₹12,904.05 million) plus additional unsubstantiated claims, alleging losses from the termination of a Contract Manufacturing Agreement for the Sputnik Light Vaccine.

Biolexis refutes the claims, citing Prestige's lack of readiness, and has counter-claimed for a 100% refund of a Capacity Fee of USD 13.62 million (approx. ₹1,289.27 million) paid to Prestige.

The Group has not acknowledged these claims as debts and believes Prestige's claims are "false, baseless, and misconceived." The matter is pending.

Subsidiaries Information

The consolidated results include the following entities:

1. OneSource Specialty Pharma Limited (Parent)

2. OneSource Specialty PTE. Limited (wholly owned subsidiary)

3. Strides Pharma Services Private Limited (wholly owned subsidiary)

4. Biolexis Private Limited (wholly owned subsidiary)

5. OneSource Specialty Pharma Inc (wholly owned subsidiary)

6. OneSource Softgels PTE. Ltd. (step-down subsidiary)

7. Biolexis PTE. Ltd (step-down subsidiary)

The auditor's review report notes reliance on the review reports of other auditors for two subsidiaries whose financial information is not material to the Group.

#Tags: #OneSourceSpecialtyPharma #Q1FY27Results #SEBIRegulation33 #FinancialResults #LitigationUpdate